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The pictures from the city centre of
Havana are familiar: the crumbling
colonial style buildings and classic
cars that miraculously survived half
a century have provided the
picturesque backdrop of movies
like Buena Vista Social Club. Just a
couple of kilometres west of the
Buena Vista district, however, there
are dramatically different sights to
be seen: a whole cluster of state of
the art research centres in modern,
purpose-built dwellings.
One of them is the Centro de
Inmunología Molecular (CIM), built
10 years ago. Its central control
room could easily serve a nuclear
power station. It reveals at first
glance that the centre is involved
in large scale production as well as
in research. It currently produces
several kilograms of monoclonal
antibodies per year, and is soon to
step up to more than a kilogram
per month. Not to mention growth
factors, vaccines, and other drugs.
While the first consideration is
always the supply of affordable
drugs for the pioneering Cuban
health system, some products are
sold commercially, such that the
centre is already funding its own
research. 
At the research front,
collaborations with European and
Canadian laboratories are bearing
fruit. Just recently, the centre has
published a crystal structure of a
mouse antibody which appears
promising in in the therapy of
melanoma and breast cancer, in
collaboration with researchers at
the technical university of
Göteborg, Sweden.
CIM is just one of around 20
high level research centres in the
neighbourhood of Playa. Nearby
there are:
The Centro de Ingeniería Genética y
Biotecnología, which was founded
in 1986 as the first of the “new
generation” research centres. It
employs around 400 research staff
and has developed several new
vaccines. One of the research areas
is the expression of drug proteins in
plants such as tobacco, a major
agricultural crop in the country. 
The Centro Nacional de
Investigaciones Científicas, which
dates from 1965. 
The Centro de Química
Farmacéutica, where over 60
researchers are exploiting the rich
biodiversity of the Cuban flora to
identify new natural products and
develop them into drugs and
nutriceuticals. 
And yet, one of the most
sensational success stories of
Cuban science comes from the
heart of the crumbling city of
Havana. There, on the campus of
Havana University is the Laboratory
for synthetic antigens, where a
team led by Vicente Verez has
succeeded in creating the first fully
synthetic vaccine that is fully
effective. This research is typical in
that it arose from a very specific
domestic need. Since the late 80s,
there has been a vaccine against
the meningitis pathogen
Haemophilus influenzae B (HiB),
but, as Verez explains, “it is only a
vaccine for the rich countries.” With
a cost of well over ten dollars per
child, the established vaccine is out
of reach for most of the world’s
children. According to UNICEF,
only 2 per cent get immunised, and
half a million children under five die
from HiB infection every year. 
Verez’s lab set out in 1989 to
develop a vaccine that would be
affordable for Cuba. After the
clinical trials conducted in
collaboration with Canadian
researchers showed the vaccine to
be fully effective, the Cubans now
have a Third World blockbuster
drug in their hands. The global
demand is estimated at around 500
million doses. The Cuban biotech
industry has started production and
is planning to make 50 million doses
by the end of this year. Global
coverage will however require
additional production sites on other
continents, for example in India. 
This example illustrates the
paradoxical advantage of having
advanced biotechnology centres
in a poor country. Whatever
Cuban scientists develop for their
domestic market is at the same
time likely to benefit the over 5
billion people in the world who
simply cannot afford most of the
drugs sold by the pharmaceutical
companies of the rich countries.
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Inside world: the imposing buildings of the University of Havana fail to reflect the degree of
isolation scientists working in Cuba have had to work around. (Photograph: Michael Gross) 
Even if these customers cannot
pay very much, they still represent
a huge export market for a small
country like Cuba. 
For the first time in its history,
the cash cows of tourism and
biotechnology offer Cuba the
prospect of becoming
independently viable and
economically competitive. Now
this is exactly the kind of outcome
that the US administration wants to
avoid at all cost. Earlier this year,
they tried to stop scientific journals
from publishing papers by Cuban
researchers  but many scientists in
Cuba were resigned to such
tactics. Eventually, it became clear
that such a measure would breach
the US constitution and the
government quietly backed down. 
A more serious threat to Cuban
research are the impediments to
buying vital equipment. Everybody
has such a story to tell. Typically, a
Cuban scientist would have
ordered a scientific instrument from
a European supplier, and it all went
well until one day the contacts
went cold and the shipment never
arrived. Only after prolonged
pestering would the researcher be
able to get in touch with a highly
embarrassed executive who would
say something along the lines of:
“We are very sorry but it has turned
out that a US company holds a
patent on the design of the fuse
used in this instrument, so if we sell
you one of them, they will withdraw
our licence to use that fuse.”
Cuban scientists still find channels
to buy the equipment they need,
but it often is a lengthy  and
frustrating experience. 
The second significant worry for
the otherwise infectiously cheerful
scientists on the island is internet
access. As a tourist paying in hard
dollars, you can comfortably
access the net from your hotel via
satellite. Most university
researchers, however, have to rely
on what little bandwidth there is in
the terrestrial connection to the
rest of the world. The internet
consortium insists that Cuba’s
connection must go via Florida,
ruling out politically less
troublesome alternatives like
Mexico. “There is a cable to
Florida, but it is thinner than my
little finger, more like a hair”
explains Sergio Pastrana, the
Foreign Secretary of the Cuban
Academy of Sciences, “so the
necessary bandwidth just isn’t
there”. And that results in
extremely slow and unreliable
connections — an ordinary web
page without heavy graphics may
take five minutes to load or may in
fact never arrive. Thus, there is a
serious bottleneck in the
information flow (books and
journals are also scarce for
currency reasons), which could be
fixed with less than 50 km of
fibreglass cable, if the blockade
were to be abandoned.
The present US administration
is, of course, not going to make
things better. In May it has further
restricted the amount of cash that
Cuban Americans can send their
families back home. But watch
this space. In a few years from
now, the whole world — minus the
US citizens — will be able to buy
innovative and cheap
pharmaceuticals made in Cuba.
Future US presidents may find
that reason enough to reconsider
their country’s policy. 
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Hidden assets: the Cuban Aacademy of Sciences - researchers have managed to
develop products geared to poorer countries. (Photograph: Michael Gross)
